Pharma BD Deal Intelligence
First-in-class BK polyomavirus antibody deepening Ipsen's rare-disease franchise
Full analysis, sources & comparables →Ipsen agreed to acquire Swiss biotech Memo Therapeutics AG under a definitive share purchase agreement, adding potravitug, a Phase 2 first-in-class monoclonal antibody against BK polyomavirus (BKPyV). Terms: EUR200 million upfront and up to EUR500 million in milestones (total potential consideration exceeding EUR700 million / ~$797M). Potravitug targets BK polyomavirus-associated nephropathy (BKPyVAN), a serious complication in kidney-transplant recipients with no approved therapy. The all-cash transaction is expected to close in Q3 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen S.A. / Memo Therapeutics AG (this deal) | 2026 | $797M | 66 |
| Ipsen S.A. / Exelixis Inc. | 2016 | $855M | 80 |
| Ipsen S.A. / Kartos Therapeutics, Inc. | 2026 | $1.8B | 68 |
| Ipsen S.A. / Clementia Pharmaceuticals Inc. | 2019 | $1.3B | — |
| Ipsen S.A. / Marengo Therapeutics, Inc. | 2024 | $1.2B | — |
| Ipsen S.A. / GENFIT | 2021 | $543M | — |
| Ipsen S.A. / Simcere Zaiming Pharmaceutical Co., Ltd. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2026 deals · Ipsen S.A. deals · Nephrology deals